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Abstract
Severe acute respiratory coronavirus (SARS-CoV) emerged in 2002, resulting in roughly 8000 cases worldwide and 10%
mortality. The animal reservoirs for SARS-CoV precursors still exist and the likelihood of future outbreaks in the human
population is high. The SARS-CoV papain-like protease (PLP) is an attractive target for pharmaceutical development because
it is essential for virus replication and is conserved among human coronaviruses. A yeast-based assay was established for
PLP activity that relies on the ability of PLP to induce a pronounced slow-growth phenotype when expressed in S. cerevisiae.
Induction of the slow-growth phenotype was shown to take place over a 60-hour time course, providing the basis for
conducting a screen for small molecules that restore growth by inhibiting the function of PLP. Five chemical suppressors of
the slow-growth phenotype were identified from the 2000 member NIH Diversity Set library. One of these, NSC158362,
potently inhibited SARS-CoV replication in cell culture without toxic effects on cells, and it specifically inhibited SARS-CoV
replication but not influenza virus replication. The effect of NSC158362 on PLP protease, deubiquitinase and anti-interferon
activities was investigated but the compound did not alter these activities. Another suppressor, NSC158011, demonstrated
the ability to inhibit PLP protease activity in a cell-based assay. The identification of these inhibitors demonstrated a strong
functional connection between the PLP-based yeast assay, the inhibitory compounds, and SARS-CoV biology. Furthermore
the data with NSC158362 suggest a novel mechanism for inhibition of SARS-CoV replication that may involve an unknown
activity of PLP, or alternatively a direct effect on a cellular target that modifies or bypasses PLP function in yeast and
mammalian cells.
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Introduction
Highly pathogenic respiratory viruses, like the H5N1 influenza
virus and severe acute respiratory syndrome coronavirus (SARS-
CoV), represent significant threats to public health and global
economic stability. They cause acute lung injury (ALI) that rapidly
progresses to acute respiratory distress syndrome (ARDS), the
former most notably in the elderly [1,2,3]. Moreover, after viral
clearance many SARS and H5N1 patients develop diffuse alveolar
damage (DAD) that often progresses to pulmonary fibrosis,
another devastating end stage lung disease, characterized by
dysregulated cell proliferation during wound repair[4,5,6].
SARS first emerged in China in 2002, the result of SARS-CoV
crossing the species barrier from bats followed by amplification
and additional mutations occurring in other species such as civet
cats and raccoon dogs, which allowed for transmission to humans
[7,8]. In many cases infection resulted in severe acute respiratory
disease, pneumonia and death [9,10]. Over 8000 cases and ,800
deaths were reported worldwide between 2002 and 2004 and
many patients required mechanical ventilation and intensive care
[11,12]. In late 2003 and early 2004, newly infected persons were
identified with SARS-CoV strains such as GDO3, which was
significantly different from those predominating in the 2002-2003
outbreaks [13]. These events indicate that a SARS epidemic may
recur, emerging from SARS-CoV strains circulating in bats, civets
or raccoon dogs.
The papain like protease (PLP) is an essential component of the
SARS-CoV replication machinery. PLP is a domain of the nsp3
protein that is initially synthesized as the ORF1a polyprotein
during replication, which then cleaves protease recognition sites
between nsp1/2, nsp2/3 and nsp3/4 [14]. In addition to protease
activity PLP has deubiquitination, and interferon antagonist
activities in vitro [15]. Homologues of PLP are found in all
coronaviruses so its targeting for drug discovery is likely to be
important for both SARS-CoV and other human coronaviruses.
We have developed a yeast-based assay and screening method
to identify small molecules that block SARS-CoV replication
based on their inhibition of PLP. The basis for the screen is that
forced expression of PLP in S. cerevisiae causes a pronounced slow
growth phenotype. Using this finding we screened a small
molecule library for compounds that specifically reversed the
PLP-induced slow growth phenotype. These compounds were
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then tested in cell culture models for efficacy against SARS-CoV
replication, as well as the known enzymatic functions of PLP. Here
we report that of 5 compounds that reversed the slow growth
phenotype in yeast; 1 compound, NSC158362, also significantly
blocked SARS-CoV replication in vitro with an EC50 ,1 mM.
This effect was specific for SARS-CoV replication because no
effect on influenza virus replication was observed with up to
50 mM of the inhibitory compound. A second compound,
NSC158011, was able to inhibit PLP-dependent protease activity
in a cell culture assay but this effect did not appear strong enough
to block virus replication. Interestingly, NSC158362 failed to block
the protease, deubiquitinase or anti-IFN activities of PLP. This
suggests that its target is either a novel activity of PLP or is a
cellular protein that regulates PLP function in infected cells, thus
representing new avenues of therapeutic intervention for SARS-
CoV.
Results
PLP expression slows S. cerevisiae cell growth
Previously we reported that expression of the influenza virus
NS1 protein in yeast resulted in a slow growth phenotype that
could be used to screen for specific small molecule antagonists of
NS1 [16]. We reasoned that expression of SARS-CoV proteins in
yeast may modulate cellular processes including signaling
pathways, as they do in mammalian cells, allowing for a genetic
system to analyze their function and the capability to identify
compounds that alter that function. We focused on the PLP
protease domain of the viral nsp3 protein because of its
requirement in virus infection [17]. Sequences corresponding to
the PLP domain were cloned into a plasmid containing the
galactose-inducible GAL1 promoter for controlled expression in S.
cerevisiae. The plasmid was transformed into a modified strain of S.
cerevisiae that carries disrupted alleles for two genes that control
drug efflux, PDR1 and PDR3, thus allowing for the efficient
retention of small molecules [16]. Shown in Figure 1A is a
galactose induction experiment of the PLP expressing strain
demonstrating increasing induction with increasing galactose
concentration. High-level expression of PLP was observed with
as little as 0.1% galactose, and 2% galactose was chosen for further
studies. We next analyzed the effect of PLP expression on yeast
growth in liquid media. Growth in medium containing glucose,
which represses GAL1-driven expression, resulted in both the
control and PLP strains growing equally well, as expected (data not
shown). Growth in galactose-containing medium was performed
over a 60 hour time course and the results are shown in Figure 1B.
There was a clear growth inhibition due to expression of PLP, with
the maximal differential between control and PLP strains
occurring between 30 and 50 hours after initiating growth in
galactose-containing medium.
Figure 1. SARS-CoV PLP produces a slow growth phenotype in yeast. A. Galactose induction of SARS-CoV PLP. Strain containing HA tagged
PLP under the control of the yeast GAL1 promoter was grown in the presence of 0 to 2% galactose. Protein was extracted and analyzed by anti-HA
western blot. B. Growth curve of yeast expressing either empty vector or HA tagged PLP grown in 2% galactose media.
doi:10.1371/journal.pone.0028479.g001
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Screen for chemical suppressors of the PLP-induced
slow-growth phenotype
Cells from an overnight culture were plated in a 96-well format
at 56105 cells/ml in 100 ml of galactose-containing medium in the
presence of 50 mM of each test compound or 1% DMSO as
control. Approximately 2,000 compounds from the NIH Devel-
opmental Therapeutics Program (DTP) Diversity Set library
(http://dtp.nci.nih.gov/index.html) were screened manually. Cell
growth was monitored by optical density (OD) over the course of
60 hours. Hits were identified as those producing a 1.3 fold or
greater increase in OD compared to the DMSO control.
Compounds positively affecting yeast growth were tested for
reproducibility using independent samples of each compound
obtained from the DTP. Five compounds demonstrated repro-
ducible activity and their effects on growth of the PLP strain are
shown in Figure 2A. The structures of the five compounds are
presented in Figure 2B.
Effects on PLP expression
One explanation for the restoration of yeast growth could be a
reduction in PLP protein levels. This was examined by western
blot analysis using the C terminal HA tag that was fused to PLP in
the expression construct. Cells containing the PLP plasmid were
induced with 2% galactose for 18 hours in the presence of 50 mM
of each compound. As shown in Figure 2C, expression of PLP was
unaffected by four of the five compounds, however NSC158011
triggered a significant decrease in PLP expression. These data
indicate that in yeast, with the exception of NSC158011, hits from
the screen acted either directly at the level of PLP function to
suppress the slow-growth phenotype, or alternatively they acted on
Figure 2. Compounds that reverse the slow growth phenotype. Yeast grown in media containing 2% galactose with the addition of either 1%
DMSO or 50 uM compounds dissolved in 1% DMSO. B. Structures of compounds shown in A. C. Effects of compounds on PLP expression. Western
blots were performed with protein extracted from HA tagged PLP expressing yeast grown in the presence of 2% galactose and 50 uM of each
compound and visualized with anti-HA antibody.
doi:10.1371/journal.pone.0028479.g002
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cellular processes that specifically modify or bypass PLP function
without altering its expression.
Toxicity studies
Each compound was tested for toxicity in both 293T and
VeroE6 cells to confirm the levels used in antiviral assays were safe
for cells. Cells were treated with each of the 5 compounds at 1, 50
and 100 mM concentrations for 24 hours, after which cell viability
was analyzed by the CellTiter-glo viability assay (Promega). We
found no toxicity of any of the five compounds even at 100 mM
concentration in either of the cell lines (Figure 3A and B).
Effects on SARS-CoV replication in vitro
The effect of each compound on SARS-CoV replication was
tested in Vero E6 and MA104 cells. Initially, cells were plated in
24 well plates and treated with 50 mM of each compound for 2
hours prior to infection (Figure 4). At 2 hours after treatment, the
medium was removed and the cells infected with a GFP expressing
version of SARS-CoV at an MOI of 1. After 1 hour, the cells were
washed twice with PBS and then medium containing each
compound, at the original concentration, was added. At 12 and
24 hours post infection aliquots were analyzed by plaque assay on
Vero E6 cells (Figure 4A and B) and by fluorescence microscopy
(Figure 4C). In control, DMSO treated cells, SARS-CoV grew to
,5X10 ˆ7 by 12 hours post infection and ,1610 ˆ8 by 24 hours
post infection. Of the five compounds tested, NSC158362 reduced
the viral titer by 100 fold at 12 hours post infection and greater
than 500 fold at 24 hours post infection (Figure 4A,B). At 12 hours
post infection strong fluorescence was seen for DMSO-treated cells
and those treated with NSC1614, NSC158011, NSC112796 and
NSC211736. Additionally, we observed a strong cytopathic effect
(CPE) in these cells as well as evidenced by rounding up, cell fusion
and ruffling of the plasma membrane (not shown). However in cells
treated with NSC158362 minimal GFP expression and CPE was
observed. Therefore by two independent measurements, plaque
assay and GFP expression; our data indicate that NSC158362
exhibited antiviral activity against SARS-CoV in cell culture.
We next performed a dose response experiment with
NSC158362. Cells were treated with increasing concentrations
of the compound starting at 2 hours prior to infection and
continuing through 24 hours post-infection (Figure 4D). The cell
supernatants were analyzed for virus replication at 12, 18 and 24
hours post infection. We observed a clear dose-dependent effect of
NSC158362. For all concentrations tested the greatest effects
occurred when the infection and treatment were carried out for 24
hours. Under these conditions the EC50 was less than 1 uM. The
maximal effect on replication was greater than 500 fold at a
concentration of 50 uM. These data demonstrate the strong
inhibitory effects of NCS158362 on SARS-CoV replication.
Additionally, we examined the effect of NSC158362 on viral
subgenomic RNA (Figure 4E). Vero cells were infected at an MOI
of 3 either 2 hours after NSC158362 was added, at the time of
NSC158362 addition, 2 before NSC158362 was added or 6 hours
before NSC158362 was added. SARS-CoV was incubated until 12
hours post infection, at which time RNA was extracted and viral
replication was analyzed by RT-PCR using primers specific for
subgenomic transcripts. We find that the addition of NSC158362
either prior to infection, at the time of infection or 2 hours after
infection can very efficiently inhibit virus RNA production, but by
6 hours after virus addition, the anti-viral effects of NSC158362
are significantly reduced.
Specificity of inhibition
We examined the specificity of the compounds for SARS-CoV
growth inhibition by challenging the replication of influenza virus.
MDCK cells were treated with each of the five compounds at a
concentration of 50 uM and then infected with influenza virus A/
PR/8 at an MOI of 0.1 for 48 hours (Figure 4F). As a positive
control infected cells were also treated with compound JJ3297,
which we have shown previously to dramatically inhibit influenza
virus replication through inhibition of viral NS1 protein
function[18]. We observed no reduction in influenza virus
replication with NSC159362, confirming that their effect on
SARS-CoV replication is specific.
Efficacy of compounds against SARS-CoV in human
airway epithelial cells
The analysis of efficacy in Vero E6 and MA104 cells is limited
since they are not human cells and they do not reflect the complex
architecture of the lung. We therefore used human airway
epithelial cells (HAE) to further assess the in vitro efficacy of
NSC158362 (Figure 5). HAEs are derived from primary human
airway cells and are grown on trans-wells that result in an air-
liquid interface where the apical surface of the well contains
beating cilia, clara cells and goblet cells with very little media
remaining on the surface[19]. The basolateral surface is bathed in
growth media similar to the architecture of lungs in vivo. HAEs
were treated with either DMSO or NSC158362 on the apical and
basolateral surface for 2 hours prior to infection. SARS-CoV/GFP
was added to the apical surface of the transwell at an MOI of 3 for
1 hour in a volume of 100 ml. At 1 hour, the wells were washed
twice with PBS and incubated for 3 days in the presence of
NSC158362 at 50 mM. A previous study showed that SARS-CoV
Figure 3. Toxicity assays. VeroE6 (A) or 293T (B) cells were treated
with 0, 10 uM or 100 uM of each compound in 1% DMSO for 24 hours.
Cells were analyzed for viability with the CellTiter Glo assay (Promega).
doi:10.1371/journal.pone.0028479.g003
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is only released from the apical surface of HAEs[20]. At 24, 48 and
72 hours post infection the apical surface was washed with 200 ml
of PBS and that apical wash used to assay the growth of the virus
by plaque assay on Vero E6 cells as above (Figure 5). SARS-CoV
infection of DMSO-treated HAEs had titers that of 2610 ˆ7 pfu/
ml at 72 hours post infection. However, SARS-CoV infected
HAEs treated with NSC158362 had a titer of 4610 ˆ5 pfu/ml at
72 hours post infection, a .50 fold reduction in titer. This
demonstrates that NSC158362 is effective at inhibiting SARS-
CoV replication in a physiologically relevant cell type.
Figure 4. Effects of compounds on virus growth and RNA production. VeroE6 (A) or MA104 (B) cells were treated with 50 uM of each
compound or 1% DMSO alone and infected with SARS-CoV(GFP) at an MOI of 3. Virus titer was assayed by plaque assay on VeroE6 cells after 12 and
24 hours of growth. C. Fluorescence images of SARS-CoV(GFP) infected Vero and MA104 cells at 24 hours post infection. D. Dose curve of NSC158362
on SARS-CoV growth. Various concentrations of drug were added to Vero cells 2 hours before SARS-CoV was added at an MOI of 3. Aliquots were
removed at 12, 18 and 24 hours post infection and titered on Vero cells. E. Vero cells were treated with either DMSO or NSC 158263 at -2 hours, 0
hours, + 2 hours or +6 hours after infection with SARS-CoV. RNA was isolated at 12 hours post infection and analyzed by RT-PCR for SARS-CoV specific
transcripts and GAPDH. F. MDCK cells were treated with 50 uM of each compound or 1% DMSO alone and infected with influenza A/PR/8 at an MOI of
0.1. Virus titer was determined by hemagglutination assay.
doi:10.1371/journal.pone.0028479.g004
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Effects on PLP protease activity
PLP has protease, de-ubiquitinase and IFN antagonist activities.
To explore the mechanism of NSC158362’s antiviral activity we
performed cell culture assays to determine if any of the known the
enzymatic activities of PLP were inhibited.
Previously we developed a PLP cleavage assay that makes use of
a plasmid expressing a fusion protein of nsp2/3/GFP as a reporter
for PLP cleavage [21]. If PLP activity is retained then the nsp2/3/
GFP fusion protein is cleaved into two polypeptides, one with just
nsp2 and one with nsp3/GFP. Western blotting for GFP reveals a
size shift from the full length nsp2/3/GFP to the smaller nsp3/
GFP fragment.
293T cells were co-transfected with a plasmid expressing PLP
and a plasmid expressing the nsp2/3/GFP fusion protein. Four
hours after transfection each compound under study was added to
the wells at a concentration of 100 mM and allowed to incubate
overnight. At 18 hours post transfection the cells were lysed and
analyzed by SDS-PAGE and western blotted with anti-GFP
antibody (Figure 6A). In control cells without PLP only the large
uncleaved full-length protein was observed. In contrast, in cells
expressing PLP a smaller cleaved protein was released at the
expected molecular weight. In cells treated with each of the
compounds only NSC158011 produced a decrease in the amount
of the cleavage product. However, since NSC158011 had no effect
on viral replication this suggests that the residual PLP protease
activity in these cells was enough to fully support viral replication.
Nonetheless this result demonstrates that one of the hits from the
screen had an effect on the protease activity of PLP. In
NSC158362 treated cells there was no effect on PLP-dependent
protease function, suggesting that the inhibition of PLP protease
function is not the mechanism of NSC158362’s antiviral action.
Lack of effect on PLP de-ubiquitinase activity
We next assayed for the ability of the compounds to inhibit the
deubiquitinase (DUB) activity of PLP. We have previously shown
that when PLP is co-transfected with a Flag-tagged ubiquitin
plasmid into 293T cells, complete de-ubiquitination of the proteins
in the cell is observed [21]. To assay the effect of the compounds
on PLP DUB activity, plasmids expressing PLP and Flag tagged
ubiquitin (Flag/Ub) were co-transfected into 293T cells. At 4
hours post transfection each compound was added at a
concentration of 50 mM. The cells were incubated for 18 hours
before protein was extracted and assayed for incorporation of Flag
tagged ubiquitin by western blot analysis with an anti-Flag
antibody. In Figure 6B, Flag/Ub is expressed alone in lane 2
and high molecular weight species corresponding to ubiquitinated
proteins were found. In lane 3, where PLP is co-transfected with
the Flag/Ub plasmid, a total lack of Flag-conjugated protein signal
was seen, demonstrating the strong DUB activity of PLP. In lanes
4, 6, 8, 10 and 12 the cells were treated with each compound and
transfected with only the Flag/Ub plasmid. These lanes show
equally strong ubiquitination of cellular proteins. However in lanes
5,7,9,11 and 13 where PLP was co-transfected into the treated
cells a total lack of ubiquitination signal was observed in each lane.
This suggests that there was no inhibition of PLP’s DUB activity
by any of the compounds identified including NSC158362, which
inhibited SARS-CoV replication.
Lack of effect on PLP IFN antagonism
We have previously shown PLP to be a potent IFN antagonist in
vitro [10]. Expression of PLP in cells blocks the IRF3 signaling
pathway and inhibits the induction of IFNb. Compounds that
inhibit PLP’s IFN antagonism would be expected to restore
induction of IFNb. We assayed for IFNb induction by transfecting
cells with an IFNbpromoter/luciferase reporter plasmid and
treatment with poly IC to induce the IFNbpromoter. The cells
were also transfected with our PLP-expressing plasmid (PLP/HA),
in the presence or absence of compounds (Figure 6C). At 18 hours
post transfection the cells were analyzed for luciferase induction.
None of the compounds reversed the IFN antagonism activity of
PLP/HA. We next co-transfected the reporter plasmid with a
RIG-I expressing plasmid to induce IRF3, and also the PLP/HA
plasmid. All three plasmids were co-transfected into 293T cells
and 4 hours post transfection each compound was added at a
concentration of 100 mM. At 18 hours post transfection the cells
were analyzed for luciferase induction (Figure 6D). When PLP was
not transfected with the RIG-I plasmid and the IFNb/luciferase
reporter plasmid, a robust induction of luciferase was produced
signifying a strong induction of the IFNb promoter. When PLP
was co-transfected with the other two plasmids and treated with
1% DMSO as a control, a strong inhibition of IFNb induction was
observed. However, when cells were treated with each of the
compounds PLP was still able to inhibit the induction of IFNb
expression. This indicates that none of the compounds blocked
PLP’s IFN antagonism activity.
We next tested the effect of the NSC158362 on SARS-CoV
induction of IFNb directly (Figure 6E). Vero cells were transfected
with an IFNb luciferase reporter plasmid for 18 hours. A control
transfection was performed containing the luciferase reporter
plasmid and a plasmid expressing RIG-I, a potent inducer of
IFNb. They were then treated with either DMSO or NSC158362
for 2 hours prior to an infection with SARS-CoV at an MOI of 3.
At 8 hours post infection, cells were analyzed for their ability to
induce IFNb after viral infection. We find no increased IFNb
production after treatment with NSC158362 and infection with
SARS-CoV suggesting the drug is not affecting the ability of
SARS-CoV to inhibit the innate immune response.
Discussion
Novel strategies to identify new antiviral compounds are
needed. The 2009 H1N1 pandemic, the SARS-CoV epidemic
and the emergence and spread of West Nile virus demonstrate that
current antiviral therapies will not work for all new and emergent
viruses. As the world’s human population expands and interacts
more and more with the environment, an increase in viral
outbreaks is inevitable. We have developed a novel screen for
Figure 5. Inhibition of SARS-CoV replication in human airway
epithelial cells by NSC158362. HAE cells were treated with either
1% DMSO or NSC158362 at 50 uM and infected with SARS-CoV(GFP).
The apical surface of each culture was rinsed with PBS at 24, 48 and 72
hr post infection and virus titered on VeroE6 cells.
doi:10.1371/journal.pone.0028479.g005
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antiviral compounds that is rapid, direct and does not rely on
previous knowledge of a viral protein’s function. The yeast based
screen described here was used to identify an antiviral compound
directed against the SARS-CoV papain-like protease. While the
function of PLP in SARS-CoV replication largely understood, this
was not necessary for the yeast-based screening methodology
described here to be successful. Initially, several SARS-CoV
proteins were tested in S. cerevisiae for their ability to inhibit yeast
Figure 6. Effect of compounds on PLP enzymatic function. A. PLP protease activity was assayed using a nsp2/3/GFP reporter plasmid. 293T
cells were transfected with either nsp2/3/GFP alone or with HA tagged PLP. Cells were treated with 50 uM of each compound or 1% DMSO alone and
protease activity was assayed by reduction in size of the nsp2/3/GFP fusion protein by western blot with anti-GFP antibody. B. PLP deubiquitinase
activity was assayed in cells transfected with Flag tagged ubiquitin and HA tagged PLP. 293T cells were transfected with both plasmids. Cells were
treated with 50 uM of each compound or 1% DMSO alone and deubiquitinase activity was assayed by reduction in ubiquitinated protein by western
blot with anti-Flag antibody. C and D. Effects of the compounds on PLP’s IFN antagonism ability were analyzed by poly IC treatment of RIGI
transfection of cells with and IFNb/luciferase reporter plasmid with and without PLP and the compounds. Western blot of transfected HA/PLP shown
below each graph. E. Effect of 158362 on IFN induction after infection with SARS-CoV. Vero cells were transfected with IFNb/luciferase reporter
plasmid. RIG-I was transfected in 1 set of wells as a positive control. Cells were then treated with either DMSO or 158362 for 2 hours prior to infection
with SARS-CoV at an MOI of 3. No increase in IFNb induction was seen after infection.
doi:10.1371/journal.pone.0028479.g006
SARS-CoV Inhibitor Screen
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cell growth in an inducible manner (not shown). Once identified as
strongly growth inhibited by PLP, yeast were then challenged with
the 2000 member NIH Diversity Set for compounds that reversed
the inhibition of yeast cell growth. Five compounds passed the
screen and those were tested against SARS-CoV infection in vitro,
of which 1 compound proved to be a potent antiviral.
We found that NSC158362 is able to block SARS-CoV
replication by more than 500 fold in culture. We also showed
that NSC158362 has a strong anti-SARS-CoV effect using HAE
cells, a physiological model of lung architecture containing ciliated
cells that are the in vivo target of the virus.
We do not know the precise mechanism of this compound’s
action. It was identified by the ability to reverse the PLP-induced
slow growth phenotype in yeast. The compound could be
functioning at many possible levels, including (1) blocking
PLP:host protein interactions (2) inhibiting an unknown enzymatic
activity of PLP or (3) inhibiting a cellular function that modifies
PLP or regulates its function. It could also be acting at the cell
surface in a way that triggers a modulation of the PLP-induced
signaling pathway. Finally, it could be acting downstream of the
effects of PLP in infected cells, so as to bypass the effects of PLP.
Regardless it is clear that compound NSC158362 specifically
inhibits SARS-CoV replication (but not influenza virus replication)
as well as SARS-CoV RNA production in infected cells. Further
investigation of the target of NSC158362 will likely yield novel
insights into SARS-CoV replication and also provide new avenues
for therapeutic intervention.
We examined the effect of these five hits on the known PLP
enzymatic activities including protease function, de-ubiquitination
and IFN antagonism. Interestingly, despite a lack of antiviral
activity, compound NSC158011 diminished PLP-dependent
protease activity in a cell culture assay (Figure 6A). Since the
effect on protease activity was only partial, we conclude that the
effect was not strong enough to lead to a diminution of virus
replication. The precise effect of NSC158011 on protease activity
could be due to several factors. These include (1) direct inhibition
of the protease activity (2) inhibition of a cellular protein whose
function is required for PLP activity in cells or (3) triggering the
degradation of PLP by direct binding or other mechanisms. With
the exception of NSC158011’s effect on protease activity, our
assays showed that none of the compounds had an effect on PLP’s
known enzymatic activities. We hypothesize that this compound is
either affecting an unidentified activity of PLP or that it acts at the
level of a cellular protein that modifies or bypasses the function of
PLP in cells. Given that NSC158362 is functional not only in yeast
but also in mammalian cells, it is very likely that the target of this
compound is PLP itself or a cellular protein that is highly
conserved from yeast to humans.
We have employed a novel antiviral screen to identify a
compound that specifically inhibits SARS-CoV replication in
multiple cell lines. Use of the yeast based screen to identify
antivirals is rapid and efficient, both important aspects when
dealing with newly emerging infectious diseases. Since knowledge
of the function of the viral protein is not required in order to
perform this type of small molecule screen, it can be scaled to any
size virus and rapidly initiated once the viral sequence is known of
a pathogen, potentially leading to the direct identification of lead
compounds for further adaptation and testing in vivo.
Methods
Plasmids
A previously cloned version of PLP containing a HA tag [10]
was used to PCR amplify PLP for cloning into the galactose
inducible yeast expression vector pRS416, to create pRS416/
PLP/HA. PLP/HA [10] under the control of chicken b-actin
promoter (pCAGGS-PLP/HA) and a reporter plasmid encoding
firefly luciferase under the control of IFN-b promoter (IFNb/
luciferase) were identical to those used in [10].
Yeast strains and growth
Strain 9526-6-2 (MATa his3D1 leu2D0 lys2D0 ura3D0
pdr1::KanMX4 pdr3::KanMX4) was a gift of Dan Burke. It was
derived by tetrad dissection from two parent strains that had been
modified by one step gene replacements. The pdr1::KanMX4 was
constructed in BY4741 (MATa his3D1 leu2D0 met15D0 ura3D0) and
the pdr3:KanMX4 was constructed in BY4742 (MATa his3D1
leu2D0 met15D0 ura3D0). PCR-mediated one-step gene replace-
ments, matings and tetrad dissections were performed as
described[22]. Strains 9526-6-2-pRS416 and 9526-6-2/pRS416/
PLP/HA were generated by transformation of 9526-6-2 with
plasmids pRS416 and pRS416/PLP/HA, respectively, and were
maintained on synthetic complete medium (SC) lacking uracil. For
growth experiments and library screening, a single transformed
colony was grown overnight and the cell number determined using
a Coulter counter (Beckman Coulter Corporation). The cells were
diluted to 56105 cells/ml in SC lacking uracil and containing 2%
raffinose and 2% galactose. 95 ml of this culture was added to 5 ml
of pre-plated test compounds in 96-well plates such that the final
drug concentration was 50 mM and the final DMSO concentra-
tion was 1%. The Diversity Set library (National Cancer Institute
Developmental Therapeutics Program) was used for the drug
screen. It was provided as 10 mM stocks in 100% DMSO. OD600
readings were taken every 12 hours for 60 hours using a
Thermomax microplate reader (Molecular Devices).
Virus replication assays
Confluent cell monolayers of VeroE6 or MA104 cells were
infected at an MOI of 3 with SARS-CoV/GFP. At 1 hour post
infection, virus was removed and cells washed with PBS. Media
was replaced with fresh MEM with either 1% DMSO or each
drug diluted in 1% DMSO. At the identified time points, viral
supernatant was removed and frozen at 280C until titering.
SARS-CoV titers were determined by plaque assay on VeroE6
cells and Influenza viral titers were determined by TCID50
analysis as described [16]. For influenza virus replication, MDCK
cells were infected at an MOI of 0.1 with influenza A/PR/8.
Compounds were added at the indicated concentrations 1 hour
post-infection at a final DMSO concentration of 1%. Cell
supernatants were harvested after 48 hours and analyzed by
hemagglutination assay. For SARS-CoV RNA analysis, Vero cells
were treated with 50 um of NSC158362 at either 2 hours before, 0
hours before, 2 hours after or 6 hours after infection with SARS-
CoV at an MOI of 3. At 12 hours past the zero time point, RNA
was extracted and used for cDNA production. SARS-CoV leader
containing mRNA, a sign of viral replication, was analyzed by
PCR using forward primer CTCTTGTAGATCTGTTCTC-
TAAACGAAC and reverse primer TTACTGTACTAGCAAAG-
CAATATTGTCG.
Luciferase reporter assay
To analyze the induction of IFNb genes, a luciferase reporter
assay was used in 293T cells. Two different inducers of Interferon
were used for these experiments, RIG-I and Poly IC. For RIG-I
transfection experiments, wells were co-transfected with a plasmid
containing an IFNb promoter fused to firefly luciferase (IFNb/
luciferase), a pCAGGS-PLP/HA plasmid [10], with or without
pCAGGS-RIG-I. Two hours after transfection, each compound
SARS-CoV Inhibitor Screen
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28479
was added to the individual wells and incubated for 18 hours until
analysis with the Luciferase Assay System (Promega) according to
the manufacturer’s protocol.
For Poly IC experiments, cells were co-transfected with the
IFNb/luciferase plasmid with or without the pCAGGS-PLP/HA
plasmid [10]. At two hours post transfection each compound was
added to the wells. At 18 hours post transfection, cells were
transfected with 50 ug/ml of Poly IC (Sigma Aldrich) using
Lipofectamine (Invitrogen). After an additional 6 hours incuba-
tion, cells were lysed and analyzed for luciferase induction using
the Luciferase Assay System (Promega) according to the
manufacturer’s protocol.
PLP activity assays
For protease activity experiments, PLP/HA was co transfected
with or without the nsp2/3/GFP reporter described in [10]. At 4
hours post transfection drugs were added to wells at the indicated
concentration. At 24 hours post transfection, the cells were lysed in
RIPA buffer and visualized on SDS-PAGE gels with anti-GFP
antibody (Sigma). For ubiquitination assays, a plasmid expressing
Flag tagged ubiquitin was co-transfected with or without
pCAGGS-PLP/HA and at 4 hours post transfection drugs were
added at the indicated concentrations. At 24 hours post
transfection, the cells were lysed in RIPA buffer and visualized
on SDS-PAGE gels with anti-Flag antibody (Sigma).
Human airway epithelial cells infections
Human nasal and tracheobronchial epithelial cells were
obtained from airway specimens resected from patients undergo-
ing elective surgery under UNC Institutional Review Board-
approved protocols by the UNC Cystic Fibrosis Center Tissue
Culture Core. Briefly, primary cells were expanded on plastic to
generate passage 1 cells and plated at a density of 250,000 cells per
well on permeable Transwell-Col (12-mm-diameter) supports.
HAE cultures were generated by provision of an air-liquid
interface for 4 to 6 weeks to form well-differentiated, polarized
cultures that resemble in vivo pseudostratified mucociliary
epithelium.
Apical virus inoculations were performed with 200 ml of virus
stocks applied to the apical or basolateral surfaces of HAE.
Following a 2 hour viral inoculation at 37uC, the inoculum was
removed and drugs added to the apical surface in 5 ul volume and
HAE were maintained with an air-liquid interface for the
remainder of the experiment. At the indicated time points, the
apical surface was washed with 200 ul PBS. This was then used for
titering on VeroE6 cells for viral replication analysis.
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